Welcome to our dedicated page for Masimo Corporation news (Ticker: MASI), a resource for investors and traders seeking the latest updates and insights on Masimo Corporation stock.
Masimo Corporation (NASDAQ: MASI) is a leading global medical technology company specializing in the development and manufacturing of innovative noninvasive patient monitoring technologies. For over 27 years, Masimo has been at the forefront of medical advancements, offering a wide array of sensors and devices that enhance patient care and safety. Their products are designed to provide healthcare professionals with critical information to improve clinical decision-making.
Masimo's core business is divided into two segments: healthcare and non-healthcare. The healthcare segment is the primary revenue generator, focusing on noninvasive patient monitoring technologies, hospital automation, connectivity solutions, and remote monitoring devices. Their clinically proven products are widely used in hospitals, emergency rooms, and clinical settings around the world.
The non-healthcare segment encompasses the consumer audio business, which includes the development, manufacturing, marketing, and licensing of premium and luxury audio sound products. This segment is known for its advanced audio integration technologies that appeal to audiophiles and general consumers alike.
Masimo's recent achievements include expanding their product portfolio with advanced remote monitoring solutions, partnering with leading healthcare organizations, and pioneering innovative technologies that address unsolvable medical challenges. Financially, the company is robust, showing consistent growth and a strong market presence.
Masimo’s dedication to improving lives is evident in their mission to save, extend, and enhance the quality of life across all demographics. Their innovative spirit attracts individuals who are passionate about making a significant impact in the medical field. As they continue to innovate, Masimo remains committed to providing top-tier products that meet the evolving needs of the healthcare industry.
Masimo (NASDAQ: MASI) announced the results of a study published in Clinical Medicine Insights: Pediatrics, showing the effectiveness of its Rad-G® Pulse Oximeter in detecting pneumonia in over 4,500 children under five in India. The study indicated that Rad-G helped achieve over 91% accurate case management of acute respiratory infections, reducing unnecessary antibiotic use. Researchers noted that Rad-G's usability and reliability make it suitable for low-resource settings, potentially transforming pneumonia diagnosis. The study highlights the critical need for improved pneumonia management tools in India, where pneumonia contributes to significant child mortality.
MDoloris Medical Systems has received regulatory clearance and marketing approval for its HFVI MOC-9 monitor in Japan. This innovation is the first of its kind for monitoring patients under analgosedation and anesthesia in Japan, integrating with Masimo's Root patient monitoring hub. The HFVI MOC-9 improves assessment of parasympathetic activity during surgeries, enhancing postoperative outcomes and reducing opioid use. Heiwa Bussan will exclusively market this technology in Japan, indicating strong sales potential in a significant market.
Masimo (NASDAQ: MASI) is set to participate in the Piper Sandler 33rd Annual Healthcare Conference on November 30, 2021, at 2:00 p.m. Eastern Time. The event will feature a live webcast available on the Masimo website, with a replay option for later viewing. Masimo is recognized for its advanced medical monitoring technologies and aims to enhance patient care while reducing associated costs. Its pulse oximetry technology is utilized in top hospitals globally, proving a significant impact on patient outcomes.
Masimo (NASDAQ: MASI) released findings from a study published in Frontiers in Neurology demonstrating that its SedLine® Brain Function Monitoring can significantly reduce the incidence of postoperative delirium (POD) in carotid endarterectomy patients. In a trial with 255 participants, those monitored with SedLine exhibited a 7.87% POD rate compared to 28.91% for standard monitoring (p < 0.01). The study highlights the potential for improved patient outcomes through enhanced anesthesia management using multiple EEG parameters.
Masimo (NASDAQ: MASI) will participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 4:00 p.m. Eastern Time. A live webcast can be accessed via the Masimo website, with a replay available post-event. Masimo is known for its innovative medical technologies including pulse oximetry that enhances patient monitoring. Established in 1995, their SET® technology is used globally, improving outcomes and reducing healthcare costs. For more details, visit www.masimo.com.
Masimo (NASDAQ: MASI) announced a study published in Frontiers in Aging Neuroscience indicating that its Root® monitoring platform could enhance postoperative cognitive function in elderly patients undergoing spinal surgery. The study involved 26 patients, showing that the intervention group managed with a multimodal algorithm had a higher mean postoperative MoCA score (24.80) compared to the control group (22.56). The research suggests that the algorithm's precision in monitoring could reduce the risk of postoperative neurocognitive disorder.
Masimo (NASDAQ: MASI) has launched Dual SET® Pulse Oximetry for Root®, enhancing critical congenital heart disease (CCHD) screening. The CE-marked Masimo SET® MOC-9® module and the Eve™ application enable simultaneous pre- and post-ductal oxygen saturation measurements, improving newborn screening efficiency. CCHD affects 2.5 to 3 newborns per 1,000 births, necessitating early detection to reduce mortality and morbidity. Masimo's technology has shown increased screening sensitivity, enhancing newborn care and clinical workflows, although the new products are not yet FDA cleared for the U.S.
Masimo (NASDAQ: MASI) reported Q3 2021 financial results, highlighting product revenue of $307.4 million, a growth of 10.5% from Q3 2020. GAAP net income reached $57.8 million, or $1.00 per diluted share, up from $49.4 million, or $0.85 per share in the previous year. The company maintained strong operational performance with GAAP operating margins of 22.0% and non-GAAP margins at 23.0%. For full-year 2021, Masimo revised its guidance to a total revenue of $1.230 billion, representing a projected growth of 7.5%.
Masimo (NASDAQ: MASI) presented findings at ANESTHESIOLOGY 2021, demonstrating the efficacy of its PVi® technology in managing fluid administration during major oncosurgery. Researchers from Rajiv Gandhi Cancer Institute found that patients guided by PVi received significantly less fluid and exhibited fewer B-lines, indicators of extravascular lung water (EVLW), without a decrease in postoperative oxygenation compared to those using conventional CVP methods. These results highlight PVi's potential for enhanced patient care in surgical settings.
Masimo (NASDAQ: MASI) will announce its third quarter 2021 financial results on October 26, 2021, after market close. The results will be discussed in a conference call scheduled for 1:30 p.m. PT (4:30 p.m. ET), featuring CEO Joe Kiani and CFO Micah Young. Masimo is a renowned medical technology company focused on noninvasive monitoring technologies aimed at improving patient outcomes and reducing costs. The company’s drive for innovation has made its technologies integral in leading hospitals globally.
FAQ
What is the current stock price of Masimo Corporation (MASI)?
What is the market cap of Masimo Corporation (MASI)?
What is Masimo Corporation's main business?
How long has Masimo Corporation been in operation?
What are the key segments of Masimo's business?
What products does Masimo offer?
What makes Masimo's products unique?
Who uses Masimo's healthcare products?
What recent achievements has Masimo Corporation accomplished?
What is the financial status of Masimo Corporation?
What is Masimo's mission?